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A complement receptor C5a antagonist regulates epithelial to
mesenchymal transition and crystallin expression after lens
cataract surgery in mice
Rinako Suetsugu-Maki,1 Nobuyasu Maki,1 Timothy P. Fox,1 Kenta Nakamura,1 Richard Cowper.Solari,2
Craig R. Tomlinson,2 Hongchang Qu,3 John D. Lambris,3 Panagiotis A. Tsonis1
1Department

of Biology and Center for Tissue Regeneration and Engineering at Dayton, University of Dayton, Dayton, OH;
of Medicine and Pharmacology & Toxicology, Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center,
Dartmouth College, Lebanon, NH; 3Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical School,
Philadelphia, PA
2Departments

Purpose: To evaluate the effects of complement employing a mouse model for secondary cataract.
Methods: The role of complement receptor C5a (CD88) was evaluated after cataract surgery in mice. An antagonist
specific to C5a receptor was administered intraperitoneally to mice. Epithelial to mesenchymal transition (EMT) was
evaluated by alpha-smooth muscle actin (α-SMA) staining and proliferation by bromodeoxyuridine (5-bromo-2'deoxyuridine, BrdU) incorporation. Gene expression patterns was examined by microarray analysis and quantitative
polymerase chain reaction (QPCR).
Results: We found that administration of a C5aR antagonist in C57BL/6J mice decreases EMT, as evidenced by α-SMA
expression, and cell proliferation. Gene expression by microarray analysis reveals discreet steps of gene regulation in the
two major stages that of EMT and lens fiber differentiation in vivo. A hallmark of the microarray analysis is that the
antagonist seems to be a novel stage-specific regulator of crystallin genes. At week two, which is marked by lens fiber
differentiation genes encoding 12 crystallins and 3 lens-specific structural proteins were severely down-regulated.
Conclusions: These results suggest a possible therapeutic role of an antagonist to C5aR in preventing secondary cataracts
after surgery. Also these results suggest that crystallin gene expression can be regulated by pro-inflammatory events in
the eye.

A major complication of cataract surgery is the formation
of secondary cataracts [1]. After lens fiber removal, some lens
epithelial cells do remain attached in the capsular bag that is
left behind to hold in place the artificial lens. In many cases
these lens epithelial cells proliferate and transdifferentiate to
mesenchymal cells, thus clouding the artificial lens1. This
complication requires costly laser treatment. In the past few
years it was found that mice and rats are in fact good models
for such studies [2-4]. After performing cataract surgery in
mice (and rats) it was found that a substantial part of the lens
is regenerated. However, early in this process epithelial to
mesenchymal transition (EMT) does take place as well.
Consequently, this system can be used to study EMT because
of the vast genetic resources existing for these animals. In our
previous studies we found, by microarray analysis, that
several members of the complement system are upregulated
during the early steps of lens regeneration, which is also
characterized by EMT [5]. Also, complement activation has

been linked with EMT of renal proximal tubular epithelial
cells leading to renal fibrosis [6]. We have reasoned that
inhibiting the function of such molecules might impede EMT.
As a first step we have decided to analyze the effect of
complement component 5 (C5) in this system.
Our results clearly show that an antagonist of C5a
receptor delays proliferation and EMT significantly both in
vivo and in vitro. Examination of global gene expression is
consistent with the effects of the antagonist on the cellular
events taking place during lens regeneration. In particular it
is shown that this antagonist might be a novel stage-specific
regulator of crystallin synthesis.
METHODS
Cataract surgery and C5aR antagonist administration:
C57BL/6J mice (eight weeks old, female purchased from
Jackson laboratory, Bar Harbor, ME) were anesthetized with
either intraperitoneal or subcutaneous injection of Ketamine
(95 mg/kg; Sigma-Aldrich, St. Louis, MO) and Xylazine
(14.3 mg/kg; Sigma-Aldrich). Mice were also subcutaneously
given the analgesic Buprenorphine (1 mg/kg; Sigma-Aldrich)
preemptively. After corneal incision anterior capsulerectomy
was performed. The lens core and fiber cells were broken by
forceps and removed from the lens capsule gently. The
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capsule was washed with 1× PBS containing Mg2+ and Ca2+
to remove fiber cells. A specific antagonist of C5a receptor
(PMX53), cyclic hexapeptide Ac-Phe-[Orn-Pro-dCha-TrpArg], was used [7]. Following surgery, mice were injected
with the peptide (1 mg/kg bodyweight, in PBS) into the
abdominal cavity every 2 days. Control mice were injected
with Ac-Phe-[Orn-Pro-dCha-Ala-dArg] at the same
concentration, also intraperitoneally. Control and
experimental peptides were not injected in the eyes. Samples
were taken 1, 2, or 3 weeks post-surgery and examined
histologically or processed for microarray analysis. The
authors confirm adherence to the ARVO statement for the use
of animals in ophthalmic & vision research.

Microarray Scanner System and further processed with the
Agilent Feature Extraction Software.
The Limma Bioconductor package was used to identify
differentially expressed genes. Data preprocessing was
performed by subtracting background from signal intensities
and separately normalizing each of the arrays with the loess
method [8-10]. Differential expression was assessed by means
of the linear models and empirical Bayes method proposed by
Smith et al. [11]. The KEGG spider web-based tool was used
to identify enriched Gene Ontology (GO) categories in the
lists of differentially expressed genes [12]. The R language
and environment for statistical computing [13] was used to
manipulate and graph data.
In vitro culture of lens capsular bags: Culture of adult mouse
lens capsular bags was performed as described previously
with some modifications [14]. Lenses were removed from
adult mice eye by dissection. They were then treated with
0.25% Tripsin/EDTA for 5min at room temperature and
rinsed with culture medium, 10% FBS/DMEM including
Penicillin/Streptomycin. Then an incision was made in the
anterior lens capsule, from which the lens fibers cell mass was
removed by forceps. The capsular bags were pinned on a 3 cm
cell culture dish (#430165; Corning Lowell, MA) with 6 to 8
entomological pins (D1; Watkins and Doncaster, Kent, UK)
and incubated with medium for 30 min at 37 °C. Following
that capsules were photographed using a microscope (TS100;
Nikon, Tokyo, Japan) with a CCD camera (Cool SNAP cf2;
Photometrics, Tucson, AZ) and imaging software
(Metamorph; Molecular Devices, Eugene, OR). This was our
day 0 samples. We then treated the cultured capsular bags with
either the C5aR antagonist or control peptide (final 1 μg/ml)
and incubated them at 37 °C in a 5% CO2 environment. We
followed the cultures and recorded progression of cell
proliferation migration and EMT at 1, 2, and 3days after
initiation of the treatment. To examine proliferation BrdU
(final 50 μg /ml) was added for 3 h before fixation.

Evaluation of EMT and cell proliferation: Eyeballs were
collected and fixed in 4% Paraformaldehyde (Acros Organics,
Morris Plains, NJ) overnight, at 4 °C, and processed for
paraffin embedding. Sections of 15 μm were stained with
hematoxylin and eosin (HE) or processed for
immunohistochemical staining with mouse alpha-smooth
muscle actin Ab (alpha-SMA Ab; 1/500 dilution; SigmaAldrich), O/N at 4 °C. This step was followed by addition of
secondary FITC or Cy3 conjugated anti-mouse IgG (1/100
dilution) for 90 min at room temperature. 5-Bromo-2’deoxyuridine (BrdU; #B5002; SIGMA) was administered to
mice 1 day before collecting eyes by i.p. injection, at 500 mg/
kg bodyweight. Sections were treated with 3N HCl for 10 min
at room temperature before blocking and 1st antibody
application (mouse anti-BrdU, #MAB3510, 1/100 dilution;
Millipore, Billerica, MA). Pictures of immunohistochemistry
were taken using a microscope (BX51; Olympus, Tokyo,
Japan) with a CCD camera (Cool SNAP cf2; Photometrics,
Tucson, AZ) and imaging software (Metamorph; Molecular
Devices, Eugene, OR). For statistical analysis we used the
Student’s t-test.
Microarray analysis: Microarray hybridization and analysis
were performed as described in Medvedovic et al. [5]. Eyes
were collected 1, 2, and 3 weeks after surgery and stored in
RNAlater (Ambion, Austin, TX) at −70 °C. Mice were
injected with C5aR antagonist or control peptide every 2 days
i.p. Experimental (C5) and control mRNAs were labeled with
Cy3 or Cy5 fluorescent dyes using the Agilent Low RNA
Input Fluorescent Linear Amplification Kit (Agilent, Santa
Clara, CA). Two-color samples were prepared and hybridized
using Agilent’s Multi-Pack Gene Expression Microarray
platform according to Agilent instructions and using Agilent
reagents. The design consisted of 60-mer oligonucleotide
probes arrayed in four 44 K individual microarrays printed on
a single glass slide, each covering the whole genome of the
mouse (catalog number G4122F, design ID 014868; Ambion,
Austin, TX). Each microarray is composed of approximately
41,000 unique biologic features and several hundred positive
and negative controls. Each biologic sample was run in
quadruplicate with a dye-flip design, scanned with an Agilent

Quantitative PCR: Regenerated lenses were collected using a
mouth pipette. RNA was purified using Nucleospin
(Macherey-Nagel, Bethlehem, PA). Room temperature (RT)
reaction was performed with a first-strand cDNA synthesis kit
(Amersham Bioscience, Piscataway, NJ) using an oligo(dT)
primer. qPCR was performed using a iQ SYBR green
supermix (Bio-Rad, Hercules, CA) and the following primers:
To quantitate the expression of each gene, Ct values were
compared to a standard curve generated using a series of
dilutions of cloned cDNAs. Specific PCR amplifications were
confirmed by melting curve analysis and by sequencing.
crystallin alpha A (CryaA) F: 5′-GAG ATT CAC GGC AAA
CAC AAC-3′, R: 5′-CAT TGG AAG GCA GAC GGT AG-3′;
crystallin alpha B (CryaB) F: 5′-ACT CAA AGT CAA GGT
TCT GGG-3′, R: 5′-GGG ATG AAG TGA TGG TGA
GAG-3′; crystallin beta B2 (CrybB2) F: 5′-CCA TTC CCA
CGA GCT CAG-3′, R: 5′-TCG CCC TTT TCA AAC ACA
950
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Figure 1. Effects of C5aR antagonist on EMT of lens epithelial cells cataract surgery in vivo. EMT was assessed by staining of sections with
alpha-SMA 1, 2, and 3 weeks after removal of lens fibers. Sections were counter-stained with Hoechst. All sections are compared from the
same region (posterior part of the eye as shown by the green rectangle in the illustration). Note the decrease in alpha-SMA signal one week
after the operation in the C5aR antagonist-treated animals when compared with the control (A, D; also depicted in the adjacent illustration).
Alpha-SMA positive area was gradually decreased even in control animals 2 and 3weeks post-operation (B, C, E, and F) showing similar
levels in both groups. 20×.

less and remain as a monolayer in the treated animals, while
in the untreated ones the positive cells are multilayered. To
better quantitate the results of Figure 1 we measured the area
of alpha-SMA stained regions in the sections. We were able
to show that at week 1 time point there was a clear and
statistically significant difference in the number of EMT
positive cells, obviously affected by the treatment with the
C5aR antagonist (Figure 2A). Likewise we observed same
kind of difference in the proliferating cells as indicated by the
incorporation of BrdU. It is clear from these results that C5aR
is important for the early stages of the regeneration process,
which is dominated by EMT and that its inhibition brings the
levels of EMT to levels observed at later stages, 2 and 3 weeks
post-operation.
To better examine this effect of C5aR antagonist we
performed an in vitro experiment where capsular bags were
cultured. It has been show before that isolation and culture of
lens capsular bags is a great model to study migration,
proliferation and EMT [1]. Capsular bags were cultured for
three days in the presence or absence of the C5aR antagonist.
Migration was observed and we found that it was inhibited in

AAC-3′;
glyceraldehyde-3-phosphate
dehydrogenase
(GAPDH) F: 5′-GCC TCG TCT CAT AGA CAA GAT G-3′,
R: 5′-CAG TAG ACT CCA CGA CAT AC-3′.
RESULTS AND DISCUSSION
After removal of the lens fibers, regeneration of the lens was
followed for three weeks. As it has been reported before
during this period of time epithelial cells transit to
mesenchymal cells and also differentiate to lens fiber cells as
well [4]. In fact it was found that by week 1 after the operation
there was quite extensive EMT, which was later subsided as
lens fibers were differentiated. In other words we have two
critical stages, one during the first week marked by
upregulation of extracellular matrix and EMT and the other
(week 2 and 3) marked by upregulation of lens structural
proteins and lens differentiation. We examined samples at
week 1, 2, and 3 after the operation. Samples were stained
with alpha-SMA to detect EMT in both controls and C5aR
antagonist-treated animals. The results are shown in Figure 1.
Immunohistochemistry showed a marked decrease of EMT in
C5aR antagonist treated mice. Alpha-SMA positive cells were
951
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Figure 2. Quantitation of EMT and cell
proliferation. Quantitation of a-SMA
positive area (A) and BrdU-positive
cells (B) in control (blue) and C5aR
antagonist-treated animals (red). These
graphs were made from sections
received in the experiment described in
Figure 1. Panel A confirms that C5aR
antagonist caused delay of EMT but also
affected proliferation of lens epithelial
cells as well. The asterisks indicate the
time when the results are statistically
significant, p=0.042<0.05 for α-SMA
and p=0.02<0.05 for BrdU/Hoechst.
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Figure 3. Effects of C5aR antagonist on cell migration, proliferation and EMT in lens capsular bag cultures. A-C: Cell migration of lens
epithelial cells treated with control peptide viewed at day 0, 1, 2, and 3, respectively. E: a-SMA staining in control peptide-treated capsular
bags 3 days in culture. F-J: Similar series with C5aR antagonist-treated capsular bags. Note that in capsular bags cultured with C5aR antagonist,
migration of cells was slower than control. Also note that EMT as was evidenced by a-SMA staining was significantly reduced in the treated
cultures (compare E to J). K: BrdU positive cells in both control experimental cultures (statistically significant by t-test; p<0.05).

the C5aR antagonist-treated cultures. This can be easily seen
in Figure 3A-D (control) and Figure 3F-I (C5 antagonisttreated). EMT was also significantly inhibited as can be seen
in Figure 3E (control) and Figure 3J (experimental). Note that
proliferation was also significantly affected in the treated
capsular bags (Figure 3K). It should be noted here that after
day 1 (and especially in control cultures) cells form multilayers obscuring correct evaluation of proliferation (thus we
present the effects on proliferation only at day 1.

stages of lens fiber differentiation and lens regeneration. An
interesting paper using the same mouse model for cataract
surgery has shown that the operation induces proinflammatory gene expression in retina. Among the regulated
genes are members of the complement system [15]. It is
obvious then that the effects of the operation could affect gene
expression in other tissues of the eye. Likewise, the effects of
the C5aR antagonist could also be mediated by inflammationrelated factors. C5 has been implicated in many different
cellular events by controlling proliferation, as during liver
regeneration [16,17]. We were therefore interested to examine
gene expression in the control and C5aR antagonist-treated
animals. After operation and treatment we collected eyes at
week 1, 2, and 3, isolated RNA and used it as probes for
microarray analysis. The microarray experiment was planned
to compare the control with the C5aR antagonist-treated mice
at the different time points (control week 1 versus C5aR
antagonist week 1, and so on). This experiment does not
compare week 1 expression with week 2 or week 3.We then
listed the genes that were differentially regulated due to the
treatment. The results were quite interesting and consistent
with the events that we have observed so far. The results are
shown in Figure 4 and the different groups in the pies are the
groups that are regulated because the C5aR-antagonist
treatment. A hallmark in the regulated genes was down
regulation of crystallin genes. At week 1 there was downregulation of γD-crystallin and βB1-crystallin genes only.
However, week 2 was marked by widespread down-regulation
of several crystallin genes (Table 1). Apart crystallin genes,

So far our results show conclusively that C5 antagonist
treatment leads to reduced proliferation and EMT of the lens
epithelial cells attached to the capsule. Our purpose for this
was to assess possible therapeutic value of the treatment.
In a previous study [5] we had analyzed in details gene
expression patterns in control mice undergoing lens
regeneration after cataract surgery and compared them with
the intact lens. As in the present study, regenerating lens had
been isolated, RNA was extracted and gene expression
patterns were compared at week 1, 2, and 3. It was striking
from that analysis that week 1 lens was dominated by
upregulation in extracellular factors as well as complement
components (that is why we also selected to study the
complement system in more details in the present study). Also
at week 1 and 2 there was a significant down-regulation of
crystallins. However, after that period and especially at
week-3 genes that encode for the structural constituents of the
lens fibers were significantly upregulated to the levels of intact
lens. That study confirmed that during the lens regeneration
event we had an early stage with domination of EMT and later
953

Molecular Vision 2011; 17:949-964 <http://www.molvis.org/molvis/v17/a105>

© 2011 Molecular Vision

Figure 4. Microarray analysis. The
complete lists are presented in
Appendix 1. For each gene the degree of
down- or upregulation due to the
treatment is recorded. In this Figure the
pies show differentially regulated genes
grouped according to their function.
Upper pie: regulated genes at week 1
after operation. Note that most regulated
genes due to the C5aR antagonist
treatment are related to extracellular
matrix most likely indicating active
migration. Middle pie: regulated genes
at week 2 after operation. Note that the
largest group is the one containing
structural constituents of eye lens,
indicating regulation of crystallin genes
(see also Table 1). Lower pie: regulated
genes at week 3 after operation. Only
genes related to visual perception and
immune response are regulated (as
being statistically enriched). CC, BP,
and MF are the three domains of Gene
Ontology,
Cellular
Component,
Biologic Process, and Molecular
Function, respectively.

there was consistent regulation of genes depending on the
events that take place. At week 1 and week 2 we observed that
among the down regulated genes there were ones involved in
cytoskeleton, fibrogenesis, myogenesis, and extracellular
matrix while genes involved in inflammation, such as ones in
interferon regulation and interleukin 1 beta were among the
upregulated ones (Table 2,Table 3,Table 4,Table 5, and
Appendix 1). Interestingly, there were only very few
upregulated genes in the treated eyes at week 2. Finally by
week 3 most of the regulation occurred in components of
visual perception and immune response. Interestingly among
the upregulated ones were aquaporin 5, important for lens
transparency as well as cytoskeletal protein-encoding genes
(Table 6,Table 7, and Appendix 1). In Table 2,Table 3,Table
4,Table 5,Table 6, and Table 7 only the top 25 regulated genes
are shown and some genes of interest are highlighted in red
(full list in Appendix 1). In Figure 4 the regulated gene groups
are presented as parts of a pie. It is evident from the expression
studies that gene regulation due to C5aR inhibition does

follow a stage-specific pattern. First there is regulation of
factors that are involved in extracellular matrix (important for
cell migration) and proliferation and then there is regulation
of lens fiber-specific genes. Our previous studies on gene
expression during lens regeneration [5] had indicated that
crystallin expression levels at week 3 after surgery were very
similar to un-operated intact lens. So obviously, in our system,
the most critical stage for lens fiber differentiation is week 2.
And this is the time that we see most down-regulation of
crystallin genes due to C5aR inhibition. To verify these results
we also performed QPCR analysis using primers specific for
CryaB,CrybB2, and CryaA. The results clearly showed that
all these three genes were indeed down-regulated by the C5aR
antagonist treatment (Figure 5). This interesting finding
suggests a novel role of C5aR antagonist in stage-specific
crystallin gene regulation. Collectively, our data indicate a
novel role of C5aR antagonist in secondary cataract formation
by negatively affecting both EMT and lens fiber
differentiation of the remaining lens epithelia cells in the
954

Gene symbol
Week 1
Crygd
Crybb1
Week 2
Crygd
Cryga
Crygc
Crybb3
Crybb1
Cryaa
Crybb2
Cryba4
Crygf
Crygn
Cryab
Cryba1
Bfsp1
Lenep
Bfsp2

C5
0.857
2.0434
35.2252
29.4933
79.0894
36.1689
15.2235
98.3355
121.6081
85.449
1.0844
2.6886
182.0757
278.2914
7.6191
0.8412
8.2683

p value

0.0295
0.049

0.0004
0.0003
0.0007
0.0064
0.0067
0.0096
0.0099
0.013
0.0476
0.028
0.0361
0.0435
0.0013
0.0179
0.0417

77.7724
63.9658
165.1198
61.9493
25.577
161.5709
197.3289
136.8441
1.7216
4.1197
272.6681
407.5949
14.4174
1.3748
12.1496

4.8861
3.8395
0.45
0.46
0.48
0.58
0.60
0.61
0.62
0.62
0.63
0.65
0.67
0.68
0.53
0.61
0.68

0.18
0.53

Mus musculus crystallin, gammaD
Mus musculus crystallin, gammaA
Mus musculus crystallin, gammaC
Mus musculus crystallin, beta B3
Mus musculus crystallin, beta B1
Mus musculus crystallin, alpha A
Mus musculus crystallin, beta B2
Mus musculus crystallin, beta A4
Mus musculus crystallin, gamma F
Mus musculus crystallin, gamma N
Mus musculus crystallin, alpha B
Mus musculus crystallin, beta A1
Mus musculus beaded filament structural protein in lens
Mus musculus lens epithelial protein
Mus musculus beaded filament structural protein 2 in lens

Mus musculus crystallin, gammaD
Mus musculus crystallin, beta B1

TABLE 1. REGULATION OF CRYSTALLIN GENES DUE TO C5 ANTAGONIST.
Control
C5/Control
Description
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C5_1W
0.86
1
1.37
32.92
19.02
0.7
2.04
0.4
0.51
65.76
0.67
0.6
0.53
0.58
1.6
0.82
0.77
0.53
0.41
43.09
2.14
0.62
1.19
12.03
0.51

Control_1W
4.89
3.78
3.56
70.44
40.27
1.37
3.84
0.73
0.91
114.52
1.15
1.03
0.91
0.99
2.67
1.29
1.2
0.81
0.63
66.14
3.28
0.95
1.8
18.17
0.77

C5/Control
0.18
0.27
0.39
0.47
0.47
0.51
0.53
0.55
0.56
0.57
0.58
0.58
0.58
0.59
0.6
0.63
0.64
0.65
0.65
0.65
0.65
0.66
0.66
0.66
0.66

TABLE 2. GENES DOWN-REGULATED 1WEEK AFTER OPERATION.
Description
Mus musculus crystallin, gamma D (Crygd), mRNA [NM_007776]
Mus musculus sarcolipin (Sln), mRNA [NM_025540] Ca2+ transport
PREDICTED: Mus musculus myosin, heavy polypeptide 3, skeletal muscle, embryonic (Myh3), mRNA [XM_354614]
Mus musculus hemoglobin, beta adult major chain (Hbb-b1), mRNA [NM_008220]
Mouse alpha-globin mRNA. [M10466]
PREDICTED: Mus musculus sodium channel, voltage-gated, type II, alpha 1 (Scn2a1), mRNA [XM_909341]
Mus musculus crystallin, beta B1 (Crybb1), mRNA [NM_023695]
Mus musculus Rho GTPase activating protein 5 (Arhgap5), mRNA [NM_009706]
Mus musculus ring finger and SPRY domain containing 1 (Rspry1), mRNA [NM_026274]
Mus musculus procollagen, type I, alpha 1 (Col1a1), mRNA [NM_007742]
Mus musculus prostate stem cell antigen (Psca), mRNA [NM_028216]
Mus musculus matrilin 4 (Matn4), mRNA [NM_013592] ECM organization
Mus musculus round spermatid basic protein 1-like (Rsbn1l), mRNA [NM_001080977]
Mus musculus AT motif binding factor 1 (Atbf1), mRNA [NM_007496]
Mus musculus WAP four-disulfide core domain 3 (Wfdc3), mRNA [NM_027961]
Mus musculus cDNA sequence BC003885 (BC003885), mRNA [NM_198609]
Mus musculus solute carrier family 17 (anion/sugar transporter), member 5 (Slc17a5), mRNA [NM_172773]
Mus musculus RIKEN cDNA 1110061N23 gene (1110061N23Rik), mRNA [NM_176834]
Mus musculus runt related transcription factor 2 (Runx2), mRNA [NM_009820] Trnascription factor, mesenchymal stem cells
Mus musculus cytochrome P450, family 2, subfamily a, polypeptide 5 (Cyp2a5), mRNA [NM_007812]
Mus musculus myosin, heavy polypeptide 7, cardiac muscle, beta (Myh7), mRNA [NM_080728]
Riken cDNA C130021I20 gene [Source:MarkerSymbol;Acc:MGI:3639863] [ENSMUST00000065087]
Mus musculus osteomodulin (Omd), mRNA [NM_012050]
Mus musculus cytochrome P450, family 2, subfamily a, polypeptide 4 (Cyp2a4), mRNA [NM_009997]
RIKEN cDNA 4933437N03 gene [Source:MarkerSymbol;Acc:MGI:1914033] [ENSMUST00000035891]
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Control_1W
0.47
0.36
0.43
2.87
0.66

0.64
0.41
0.61
0.43
0.36
0.37
0.41
2.61
0.37
2.16
0.37
0.74
0.39
1.18
0.4
8.39
0.7
0.38

0.38
1.52

C5_1W
1.34
1.01
0.95
5.69
1.25

1.18
0.73
1.09
0.74
0.62
0.62
0.67
4.26
0.6
3.44
0.58
1.17
0.61
1.83
0.61
12.91
1.07
0.57

0.58
2.31

957
1.52
1.52

1.83
1.81
1.79
1.72
1.7
1.68
1.65
1.63
1.6
1.59
1.57
1.57
1.56
1.55
1.54
1.54
1.53
1.52

C5/Control
2.83
2.81
2.23
1.98
1.91

TABLE 3. GENES UPREGULATED 1 WEEK AFTER OPERATION.
Description
Mus musculus arachidonate 15-lipoxygenase (Alox15), mRNA [NM_009660]
Mus musculus melanoma-derived leucine zipper, extra-nuclear factor (Mlze), mRNA [NM_031378]
Mus musculus cell death-inducing DFFA-like effector c (Cidec), mRNA [NM_178373]
Mus musculus Z-DNA binding protein 1 (Zbp1), mRNA [NM_021394]
Mus musculus 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030459M14
product:unclassifiable, full insert sequence. [AK031607]
Mus musculus coiled-coil domain containing 100 (Ccdc100), mRNA [NM_178686]
Mus musculus membrane-spanning 4-domains, subfamily A, member 4B (Ms4a4b), mRNA [NM_021718]
Mus musculus ras responsive element binding protein 1 (Rreb1), transcript variant 1, mRNA [NM_001013392]
Mus musculus interferon regulatory factor 1 (Irf1), mRNA [NM_008390]
Mus musculus CD5 antigen (Cd5), mRNA [NM_007650]
Mus musculus RIKEN cDNA 4930511J11 gene (4930511J11Rik), mRNA [NM_029070]
nucleotide binding protein 1 [Source:MarkerSymbol;Acc:MGI:1347073] [ENSMUST00000023146]
Mus musculus RIKEN cDNA 2310016F22 gene (2310016F22Rik), mRNA [NM_173743]
Mus musculus ubiquitin D (Ubd), mRNA [NM_023137]
Mus musculus myelin basic protein (Mbp), transcript variant 7, mRNA [NM_010777]
Mus musculus activity-dependent neuroprotective protein (Adnp), mRNA [NM_009628]
Mus musculus brain derived neurotrophic factor (Bdnf), transcript variant 1, mRNA [NM_007540]
Mus musculus proprotein convertase subtilisin/kexin type 1 (Pcsk1), mRNA [NM_013628]
Mus musculus cDNA sequence BC048679 (BC048679), mRNA [NM_183143]
Mus musculus translocase of outer mitochondrial membrane 40 homolog (yeast) (Tomm40), mRNA [NM_016871]
Mus musculus interferon inducible GTPase 1 (Iigp1), mRNA [NM_021792]
Mus musculus thyroid hormone receptor interactor 4 (Trip4), mRNA [NM_019797]
Mus musculus 0 day neonate thymus cDNA, RIKEN full-length enriched library, clone:A430106H13
product:tripartite motif-containing 35, full insert sequence. [AK020775]
Mus musculus transmembrane protein 48 (Tmem48), mRNA [NM_028355]
Mus musculus coagulation factor X (F10), mRNA [NM_007972]
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Control_2W
77.77
5.72
63.97
165.12
1.32
14.42
1.26
48.97
8
3.98
61.95
5.4
4.79
25.58
1.37
1.2
2.86
161.57
1.09
9.5
1.37
2.27

197.33
3.51
0.9

C5_2W
35.23
2.61
29.49
79.09
0.64
7.62
0.69
26.91
4.43
2.3
36.17
3.19
2.83
15.22
0.82
0.73
1.73
98.34
0.66
5.79
0.84
1.39

121.61
2.17
0.56

958
0.62
0.62
0.62

C5/Control
0.45
0.46
0.46
0.48
0.49
0.53
0.55
0.55
0.55
0.58
0.58
0.59
0.59
0.6
0.6
0.6
0.61
0.61
0.61
0.61
0.61
0.61

TABLE 4. GENES DOWN-REGULATED 2 WEEKS AFTER OPERATION.
Description
Mus musculus crystallin, gamma D (Crygd), mRNA [NM_007776]
Mus musculus complement factor D (adipsin) (Cfd), mRNA [NM_013459]
Mus musculus crystallin, gamma A (Cryga), mRNA [NM_007774]
Mus musculus crystallin, gamma C (Crygc), transcript variant 1, mRNA [NM_007775]
Unknown
Mus musculus beaded filament structural protein in lens-CP94 (Bfsp1), mRNA [NM_009751]
Mus musculus fibronectin 1 (Fn1), mRNA [NM_010233]
Mus musculus procollagen, type I, alpha 1 (Col1a1), mRNA [NM_007742]
Mus musculus lactase-like (Lctl), mRNA [NM_145835]
Mus musculus serine (or cysteine) peptidase inhibitor, clade F, member 1 (Serpinf1), mRNA [NM_011340]
Mus musculus crystallin, beta B3 (Crybb3), mRNA [NM_021352]
Mus musculus procollagen, type V, alpha 1 (Col5a1), mRNA [NM_015734]
Mus musculus fibromodulin (Fmod), mRNA [NM_021355]
Mus musculus crystallin, beta B1 (Crybb1), mRNA [NM_023695]
Mus musculus RAD21 homolog (S. pombe) (Rad21), mRNA [NM_009009]
Mus musculus X-linked lymphocyte-regulated 3B (Xlr3b), mRNA [NM_011727]
Mus musculus procollagen, type XII, alpha 1 (Col12a1), mRNA [NM_007730]
Mus musculus crystallin, alpha A (Cryaa), mRNA [NM_013501]
Mus musculus deltex 4 homolog (Drosophila) (Dtx4), mRNA [NM_172442]
Mus musculus fatty acid binding protein 4, adipocyte (Fabp4), mRNA [NM_024406]
Mus musculus lens epithelial protein (Lenep), mRNA [NM_020517]
Mus musculus 16 days embryo lung cDNA, RIKEN full-length enriched library, clone:8430418K19 product:gap junction membrane
channel protein alpha 3, full insert sequence [AK136383]
Mus musculus crystallin, beta B2 (Crybb2), mRNA [NM_007773]
PREDICTED: Mus musculus gene model 96, (NCBI) (Gm96), mRNA [XM_129042]
Mus musculus syntaxin binding protein 5 (tomosyn) (Stxbp5), mRNA [NM_001081344]
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C5_2W
0.89
1.55
1

Control_2W
0.45
0.83
0.64

TABLE 5. GENES UPREGULATED 2 WEEKS AFTER OPERATION.
C5/Control
Description
1.97
Unknown
1.88
Mus musculus chitinase 3-like 3 (Chi3l3), mRNA [NM_009892]
1.56
Mus musculus interleukin 1 beta (Il1b), mRNA [NM_008361]
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Control_3W
55.19
1.34
2.22
0.99
0.92
1.49

1.62
11.62
1.2
7.72

22.14
0.92

1.4
2.64
1.02
2.5
1.04
0.78
0.89

1.08
7.32
0.75
1.23

0.81
1.07

C5_3W
18.14
0.45
0.84
0.44
0.44
0.77

0.89
6.51
0.67
4.39

13.07
0.55

0.83
1.56
0.61
1.51
0.63
0.48
0.55

0.67
4.58
0.47
0.77

960

0.51
0.68

0.63
0.63

0.62
0.62
0.63
0.63

0.59
0.59
0.6
0.6
0.61
0.61
0.62

0.59
0.59

0.55
0.56
0.56
0.57

C5/Control
0.33
0.34
0.38
0.44
0.48
0.52

TABLE 6. GENES DOWN-REGULATED 3 WEEKS AFTER OPERATION.
Description
Mus musculus crystallin, beta B1 (Crybb1), mRNA [NM_023695]
Unknown
Mus musculus myelin basic protein (Mbp), transcript variant 7, mRNA [NM_010777]
Mus musculus cell death-inducing DFFA-like effector c (Cidec), mRNA [NM_178373]
Mus musculus adiponectin, C1Q and collagen domain containing (Adipoq), mRNA [NM_009605]
Mus musculus adult retina cDNA, RIKEN full-length enriched library, clone:A930026N13 product:retinitis pigmentosa 1 homolog (human),
full insert sequence. [AK044612]
Mus musculus LSM14 homolog B (SCD6, S. cerevisiae), mRNA (cDNA clone IMAGE:4458586), partial cds. [BC040823]
Mus musculus elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 4 (Elovl4), mRNA [NM_148941]
Mus musculus selenophosphate synthetase 2 (Sephs2), mRNA [NM_009266]
Mus musculus 0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130019F23 product:unclassifiable, full insert sequence
[AK053456]
Mus musculus guanine nucleotide binding protein, beta 1 (Gnb1), mRNA [NM_008142]
Mus musculus adult retina cDNA, RIKEN full-length enriched library, clone:A930017E01 product:unclassifiable, full insert sequence.
[AK044500]
Mus musculus pleckstrin homology domain containing, family F (with FYVE domain) member 2 (Plekhf2), mRNA [NM_175175]
Mus musculus gap junction membrane channel protein alpha 9 (Gja9), mRNA [NM_010290]
Mus musculus immunoglobulin superfamily, member 11 (Igsf11), mRNA [NM_170599]
Mus musculus zinc finger, DHHC domain containing 2 (Zdhhc2), mRNA [NM_178395]
Mus musculus RIKEN cDNA 9130404D08 gene (9130404D08Rik), mRNA [NM_028993]
Mus musculus RAR-related orphan receptor beta (Rorb), transcript variant 2, mRNA [NM_146095]
Mus musculus 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130077C01 product:unclassifiable, full insert
sequence [AK141969]
Mus musculus shroom family member 2 (Shroom2), mRNA [NM_172441]
Mus musculus cone-rod homeobox containing gene (Crx), mRNA [NM_007770]
Mus musculus protein kinase, cAMP dependent regulatory, type II alpha (Prkar2a), mRNA [NM_008924]
Mus musculus 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030496O18 product:unclassifiable, full insert
sequence [AK031720]
PREDICTED: Mus musculus golgi autoantigen, golgin subfamily b, macrogolgin 1, transcript variant 1 (Golgb1), mRNA [XM_148244]
Mus musculus 13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430019O20 product:unclassifiable, full insert sequence
[AK084964]
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C5_3W
47.14
59.19
1.15
4.34
28.41
1.71
3.28
183.41
3.6
1.79
1.02
61.8
3.07
61.67
4.59
6.36
2.1
2.15
46.63
10.92
1.32
48.92
134.36
1.7
10.31

Control_3W
24.78
33.03
0.65
2.47
16.24
0.98
1.89
110.51
2.18
1.09
0.62
37.62
1.88
38.14
2.83
3.92
1.3
1.34
28.89
6.84
0.83
31.05
85.11
1.07
6.58

C5/Control
1.9
1.79
1.76
1.76
1.75
1.75
1.73
1.66
1.65
1.64
1.64
1.64
1.63
1.62
1.62
1.62
1.62
1.61
1.61
1.6
1.6
1.58
1.58
1.58
1.57

TABLE 7. GENES UPREGULATED 3 WEEKS AFTER OPERATION.
Description
Mus musculus keratin 16 (Krt16), mRNA [NM_008470]
Mus musculus expressed sequence AI661453 (AI661453), mRNA [NM_145489]
Mus musculus synaptosomal-associated protein 23 (Snap23), mRNA [NM_009222]
Mus musculus interferon inducible GTPase 1 (Iigp1), mRNA [NM_021792]
Mus musculus phosphatidylethanolamine binding protein 2 (Pbp2), mRNA [NM_029595]
Mus musculus Z-DNA binding protein 1 (Zbp1), mRNA [NM_021394]
Mus musculus S100 calcium binding protein A9 (calgranulin B) (S100a9), mRNA [NM_009114]
Mus musculus aquaporin 5 (Aqp5), mRNA [NM_009701]
Mus musculus actin, alpha 2, smooth muscle, aorta (Acta2), mRNA [NM_007392]
Mus musculus dihydrolipoamide dehydrogenase (Dld), mRNA [NM_007861]
Mus musculus ring finger protein 146 (Rnf146), mRNA [NM_026518]
Mus musculus Kruppel-like factor 4 (gut) (Klf4), mRNA [NM_010637]
Mus musculus RIKEN cDNA 1810019J16 gene (1810019J16Rik), transcript variant 2, mRNA [NM_133707]
Mus musculus RIKEN cDNA 1600029D21 gene (1600029D21Rik), mRNA [NM_029639]
Mus musculus purinergic receptor P2Y, G-protein coupled 2 (P2ry2), mRNA [NM_008773]
Mus musculus cadherin EGF LAG seven-pass G-type receptor 1 (Celsr1), mRNA [NM_009886]
Mus musculus macrophage stimulating 1 receptor (c-met-related tyrosine kinase) (Mst1r), mRNA [NM_009074]
Mus musculus potassium inwardly-rectifying channel, subfamily K, member 6 (Kcnk6), mRNA [NM_001033525]
Mus musculus myosin, heavy polypeptide 14 (Myh14), mRNA [NM_028021]
Mus musculus wingless related MMTV integration site 10a (Wnt10a), mRNA [NM_009518]
Mus musculus basic leucine zipper transcription factor, ATF-like 2 (Batf2), mRNA [NM_028967]
Mus musculus procollagen, type XVII, alpha 1 (Col17a1), mRNA [NM_007732]
Mus musculus envoplakin (Evpl), mRNA [NM_025276]
Mus musculus RIKEN cDNA 4931406C07 gene (4931406C07Rik), mRNA [NM_133732]
Mus musculus poly (ADP-ribose) polymerase family, member 14 (Parp14), mRNA [NM_001039530]
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Figure 5. QPCR analysis of three crystallin genes. Two different samples were used from operated animals two weeks after surgery. For each
sample the analysis was in triplicates. Note that expression of these crystallin genes was down regulated in all cases due to C5 antagonist
treatment, as was the case in the microarray analysis. Statistics are as follows: CryaB-1: p=0.0000114343<0.05, CryaB-2:
p=0.0000296783<0.05, CrybB2-1: p=0.0000598278<0.05, CrybB2-2: p=0.0002057<0.05, CryaA-1: p=0.005616049<0.05, CryaA-2:
p=0.000385042<0.05.

capsule and imply that regulation of the complement
components might be therapeutically beneficial after cataract
surgery. The mechanism, however, is elusive. Normally, the
results should be attributed to C5aR-mediated signaling, but
we were unable to confirm our results in experiments where
we used capsular bags from C5aR−/− mice, nor we observed
expression of C5aR in the lens capsules (even though C5 was
present; unpublished information). One explanation could be
that this peptide does bind to other receptors, such as Masrelated G-protein coupled receptor member X2 (MrgX2) or
orphan receptor MrgX3 [18]. Alternatively, at least in vivo the
results could be explained by PMX53 mediated signaling in
other eye tissues and action to the lens by effector genes or by
mediation of inflammation-related factors. Future studies
toward that direction will elucidate these issues.
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Appendix 1. Data on the microarray analysis.
To access the data, click or select the words “Appendix
1.” This will initiate the download of a Microsoft Exel file
(.xlsx).
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